Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

Background Therapeutic options currently available for metastatic castration-resistant prostate cancer (mCRPC) do not extend median overall survival >6 months. Therefore, the development of novel and effective therapies for mCRPC represents an urgent medical need. T cell engagers (TCEs) have emer...

Descripción completa

Detalles Bibliográficos

Autores principales:	Lawrence Fong, Serena Kwek, Rong Deng, Yuping Li, Kevin Dang, Giulia Castello, Starlynn C Clarke, Aarti Balasubramani, Andrew Boudreau, Laura Davison, Katherine E Harris, Duy Pham, Preethi Sankaran, Harshad S Ugamraj, Alec Starzinski, Suhasini Iyer, Wim van Schooten, Ute Schellenberger, Wenchao Sun, Nathan D Trinklein, Roland Buelow, Ben Buelow, Pranjali Dalvi
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	BMJ Publishing Group 2021-06-01
Colección:	Journal for ImmunoTherapy of Cancer
Acceso en línea:	https://jitc.bmj.com/content/9/6/e002488.full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!